Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Current Deferred Revenue (2016 - 2022)

Usana Health Sciences has reported Current Deferred Revenue over the past 10 years, most recently at $19.6 million for Q1 2022.

  • Quarterly Current Deferred Revenue rose 23.09% to $19.6 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $19.6 million through Jan 2022, up 23.09% year-over-year, with the annual reading at $19.6 million for FY2022, 23.09% up from the prior year.
  • Current Deferred Revenue was $19.6 million for Q1 2022 at Usana Health Sciences, up from $16.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $19.6 million in Q1 2022 and troughed at $2.6 million in Q4 2018.
  • The 4-year median for Current Deferred Revenue is $14.9 million (2019), against an average of $13.0 million.
  • Year-over-year, Current Deferred Revenue fell 13.61% in 2018 and then skyrocketed 423.51% in 2019.
  • A 4-year view of Current Deferred Revenue shows it stood at $2.6 million in 2018, then skyrocketed by 423.51% to $13.9 million in 2019, then rose by 15.16% to $16.0 million in 2021, then rose by 23.09% to $19.6 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Current Deferred Revenue are $19.6 million (Q1 2022), $16.0 million (Q1 2021), and $13.9 million (Q4 2019).